Skip to main content

Peer Review reports

From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Original Submission
26 Sep 2016 Submitted Original manuscript
17 Feb 2017 Reviewed Reviewer Report - Gian Bertelli
21 Apr 2017 Reviewed Reviewer Report - Michaela Dinan
3 Aug 2017 Author responded Author comments - Frederique Penault-Llorca
Resubmission - Version 2
3 Aug 2017 Submitted Manuscript version 2
7 Aug 2017 Reviewed Reviewer Report - Gian Bertelli
18 Aug 2017 Reviewed Reviewer Report - Michaela Dinan
8 Sep 2017 Author responded Author comments - Frederique Penault-Llorca
Resubmission - Version 3
8 Sep 2017 Submitted Manuscript version 3
20 Oct 2017 Author responded Author comments - Frederique Penault-Llorca
Resubmission - Version 4
20 Oct 2017 Submitted Manuscript version 4
3 Jan 2018 Author responded Author comments - Frederique Penault-Llorca
Resubmission - Version 5
3 Jan 2018 Submitted Manuscript version 5
27 Mar 2018 Author responded Author comments - Frederique Penault-Llorca
Resubmission - Version 6
27 Mar 2018 Submitted Manuscript version 6
Publishing
4 Apr 2018 Editorially accepted
4 May 2018 Article published 10.1186/s12885-018-4331-8

You can find further information about peer review here.

Back to article page